HKSE:01541 (China)
Â
Ordinary Shares - Class H
HK$
14.48
(+3.58%)
Jun 21
Current and historical daily PE Ratio for ImmuneOnco Biopharmaceuticals (Shanghai) Inc (
) from 2023 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. ImmuneOnco Biopharmaceuticals (Shanghai) stock (HKSE:01541) PE ratio as of Jun 21 2024 is 0.
More Details
ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) PE Ratio (TTM) Chart
ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 196
- 1
- 2
- 3
| ImmuneOnco Biopharmaceuticals (Shanghai) PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-21 | At Loss | 2024-04-16 | At Loss |
| 2024-06-20 | At Loss | 2024-04-15 | At Loss |
| 2024-06-19 | At Loss | 2024-04-12 | At Loss |
| 2024-06-18 | At Loss | 2024-04-11 | At Loss |
| 2024-06-17 | At Loss | 2024-04-10 | At Loss |
| 2024-06-14 | At Loss | 2024-04-09 | At Loss |
| 2024-06-13 | At Loss | 2024-04-08 | At Loss |
| 2024-06-12 | At Loss | 2024-04-05 | At Loss |
| 2024-06-11 | At Loss | 2024-04-03 | At Loss |
| 2024-06-07 | At Loss | 2024-04-02 | At Loss |
| 2024-06-06 | At Loss | 2024-03-28 | At Loss |
| 2024-06-05 | At Loss | 2024-03-27 | At Loss |
| 2024-06-04 | At Loss | 2024-03-26 | At Loss |
| 2024-06-03 | At Loss | 2024-03-25 | At Loss |
| 2024-05-31 | At Loss | 2024-03-22 | At Loss |
| 2024-05-30 | At Loss | 2024-03-21 | At Loss |
| 2024-05-29 | At Loss | 2024-03-20 | At Loss |
| 2024-05-28 | At Loss | 2024-03-19 | At Loss |
| 2024-05-27 | At Loss | 2024-03-18 | At Loss |
| 2024-05-24 | At Loss | 2024-03-15 | At Loss |
| 2024-05-23 | At Loss | 2024-03-14 | At Loss |
| 2024-05-22 | At Loss | 2024-03-13 | At Loss |
| 2024-05-21 | At Loss | 2024-03-12 | At Loss |
| 2024-05-20 | At Loss | 2024-03-11 | At Loss |
| 2024-05-17 | At Loss | 2024-03-08 | At Loss |
| 2024-05-16 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-09 | At Loss | 2024-03-01 | At Loss |
| 2024-05-08 | At Loss | 2024-02-29 | At Loss |
| 2024-05-07 | At Loss | 2024-02-28 | At Loss |
| 2024-05-06 | At Loss | 2024-02-27 | At Loss |
| 2024-05-03 | At Loss | 2024-02-26 | At Loss |
| 2024-05-02 | At Loss | 2024-02-23 | At Loss |
| 2024-04-30 | At Loss | 2024-02-22 | At Loss |
| 2024-04-29 | At Loss | 2024-02-21 | At Loss |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-09 | At Loss |
| 2024-04-18 | At Loss | 2024-02-08 | At Loss |
| 2024-04-17 | At Loss | 2024-02-07 | At Loss |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc
ISIN : CNE100006624
Share Class Description:
HKSE:01541: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
01541.Hong Kong IPO Date
2023-09-05Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers